NVE Corporation (NVEC) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several positive aspects: ongoing production expansion, new product launches, and optimistic sales outlook in medical devices. The Q&A section highlights increased distributor sales, effective marketing efforts, and promising partnerships like Abbott. While there are some uncertainties, such as the nascent MagNav technology and lack of specific details in defense sector recovery, the overall sentiment is positive due to growth in key markets and strategic investments. The absence of negative financial surprises or guidance cuts further supports a positive stock movement prediction.
Key Financial Performance
Revenue Revenue for the third quarter of fiscal 2026 increased 23% year-over-year. The increase was due to a 16% increase in product sales and a 335% increase in contract R&D revenue. The increases were across most of our product lines and channels.
Gross Margin Gross margin for the third quarter of fiscal 2026 was 79% of revenue compared with 84% in the prior year quarter. The decrease in gross margin percentage was due to a less profitable product mix and increased distributor sales for the quarter. Distributor sales typically have lower gross margin than direct sales.
Operating Expenses Total operating expenses decreased 12% for the third quarter of fiscal 2026 compared to the third quarter of fiscal 2025 due to a 9% decrease in R&D expense and a 19% decrease in SG&A. The decrease in R&D was due to completion of some wafer level chip scale packaging activities and reassignment of some R&D resources to manufacturing. The decrease in SG&A was primarily due to the timing of selling and marketing activities and reassignment of some SG&A resources to manufacturing and new product development.
Interest Income Interest income decreased 3% due to a decrease in our marketable securities portfolio as proceeds from bond maturity, partially funded dividends and fixed asset purchases.
Other Income Other income decreased by $135,000, which is primarily from reclaiming precious metals used in our manufacturing process in the prior year quarter.
Effective Tax Rate Our effective tax rate increased to 20% for the third quarter of fiscal 2026 compared to 15% for the third quarter of fiscal 2025. The increase was primarily due to the noncash impact of tax law changes on certain tax deductions this fiscal year.
Net Income Net income increased 11% to $3.38 million or $0.70 per diluted share from $3.05 million or $0.63 per share. The increase was primarily due to increased revenue and decreased operating expenses, partially offset by decreased gross margin, a decrease in other income and an increase in our effective tax rate.
Profitability Metrics Operating margin was 60%. Pretax margin was 68% and net margin was 54%.
9-Month Revenue For the first 9 months of fiscal 2026, total revenue increased 0.4% to $18.7 million from $18.6 million for the 9 months of the prior year. The revenue increase was due to a 0.8% increase in product sales, partially offset by an 8% decrease in contract R&D.
9-Month Net Income Net income for the 9 months decreased 8% to $10.3 million or $2.12 per diluted share.
Cash Flow from Operations Cash flow from operations was $12.2 million in the first 9 months of the fiscal year.
Accounts Receivable Accounts receivable decreased $1.1 million during the first 9 months of fiscal 2026 primarily due to the timing of customer payments.
Inventories Inventories decreased by $177,000 due to increased product sales.
Prepaid Expenses and Other Assets Prepaid expenses and other assets increased $323,000 primarily due to increased accrued bond interest and a decrease in federal and state taxes due. The decrease in taxes due was because we deducted previously unamortized research and development expenses in the quarter ended December 31, 2025, as permitted under the federal budget reconciliation bill enacted July 4, 2025.
Accrued Payroll and Other Current Liabilities Accrued payroll and other current liabilities decreased $366,000 primarily due to the payments of federal and state taxes balance due as of March 31, 2025, and decreased accrual for performance-based compensation.
Fixed Asset Purchases Fixed asset purchases were $2.18 million for the first 9 months of the fiscal year, including $1.05 million in the December quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New wafer-level chip scale sensor: Announced a new sensor that is 0.65 millimeter square, about 1/3 the size of the conventionally packaged version. This allows for unmatched miniaturization and special sensitivity.
Medical devices market: Extended supplier partnering agreement with Abbott Laboratories for two years through December 31, 2027, with price increases for 2026 and 2027. Exhibited at the Medical Design & Manufacturing Trade Show, generating good leads and planning to exhibit at Medical Device & Manufacturing West.
New equipment installation: Completed installation and calibration of a new equipment cluster, increasing capacity and capabilities for precise wafer-level chip scale package parts. This equipment allows precise control of spintronic materials deposition to within 1 atomic layer.
Operational cost efficiencies: Operating expenses decreased 12% due to a 9% decrease in R&D expenses and a 19% decrease in SG&A expenses. This was achieved by reallocating resources to manufacturing and new product development.
R&D strategy: Focused on developing advanced electronics for high-value markets such as medical devices, electric and autonomous vehicles, and robotics, leveraging AI and automation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Economic Environment Uncertainties: The company acknowledges uncertainties related to the economic environments in the industries they serve, which could impact future sales and revenue.
Gross Margin Decline: Gross margin for the third quarter of fiscal 2026 decreased to 79% from 84% in the prior year quarter due to a less profitable product mix and increased distributor sales, which typically have lower margins.
Tax Law Changes: The effective tax rate increased to 20% from 15% due to noncash impacts of tax law changes, which could affect profitability.
Decreased R&D and SG&A Expenses: R&D expenses decreased by 9% and SG&A expenses by 19%, which, while reducing costs, may limit future innovation and marketing efforts.
Supply Chain and Manufacturing Risks: The company has invested in new equipment and expanded production capacity, but any delays or issues in putting this equipment into service could disrupt operations.
Revenue Dependency on Specific Markets: The company’s focus on high-value markets like medical devices and autonomous vehicles makes it vulnerable to downturns or changes in these sectors.
Regulatory and Trade Barriers: Risks related to tariffs, customs duties, and other trade barriers could impact the company’s financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Tax Rate Projections: The company expects a full-year tax rate of 16% to 17% in fiscal 2026, supported by advanced manufacturing investment tax credits of between $700,000 and $1 million to offset the impact of other tax law changes.
Capital Expenditures: The company has substantially completed spending on a two-year multimillion-dollar expansion and expects to put the new equipment into service in the current quarter, by March 31, 2026.
New Equipment and R&D Capabilities: The new equipment allows for extremely precise control of spintronic materials deposition, enabling more precise spintronic devices and expanding capacity for existing products. The equipment is expected to be operational by March 31, 2026.
Product Development and Market Focus: The company is focusing on high-value markets such as medical devices, electric and autonomous vehicles, advanced factory and humanoid robotics, and highly automated Fourth Wave Factories using AI of Things. A new wafer-level chip scale sensor was recently announced, offering unmatched miniaturization and sensitivity.
Customer Agreements: The company extended its supplier partnering agreement with Abbott Laboratories for two years through December 31, 2027, including price increases for 2026 and 2027.
Trade Show Participation and Future Sales: The company plans to exhibit at the Medical Device & Manufacturing West trade show starting February 3, 2026, to generate leads and promote its products for future sales.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Interest income: Interest income decreased 3% due to a decrease in our marketable securities portfolio as proceeds from bond maturity, partially funded dividends and fixed asset purchases.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the application of magnetic navigation (MagNav) in GPS-compromised areas and its relevance to your magnetometer sensors?
A:MagNav is a new technology replacing GPS in defense applications susceptible to GPS jamming. NVE sensors are lower power and smaller than those used in MagNav. While the technology is evolving, it is not mature enough for NVE to pursue currently. However, it is an area of interest for future opportunities.
Q:Do you have a part suitable for MagNav applications today?
A:No, MagNav is still a nascent technology with imprecise maps, making it not mature enough for NVE to chase at this time.
Q:Is the new equipment up and running on schedule?
A:Yes, the new equipment is up and running as planned. It is a complex process, but the team has done a great job staying on schedule.
Q:Will the new equipment contribute to new product sales or profitability?
A:Yes, there is optimism about the technology developed with the new equipment. Samples of new sensors are being sold, and continued sales are expected.
Q:Are distributors building up inventory again?
A:Yes, distributor sales are picking up, indicating that inventories built up during the semiconductor slowdown have been depleted, and end-user demand is increasing.
Q:How does NVE's intellectual property compare to Everspin's, and are there discussions about licensing NVE's IP?
A:NVE has excellent intellectual property, primarily used for anti-tamper and defense applications. While NVE is in a different market than Everspin, it continues to develop MRAM and sees significant value in its IP, with opportunities to monetize it through licensing.
Q:Is MRAM a replacement for Flash memory?
A:MRAM is a nonvolatile memory retaining information when power is removed. It is already used in some embedded computing systems and is considered a powerful technology for specific applications.
Q:Are there plans to expand marketing efforts?
A:Yes, NVE is increasing marketing efforts, focusing on trade shows, demonstrations, and newsletters, which have proven effective. Twitter is used more for fun and content rather than as a major sales driver.
Q:What is the traction for rare earth magnets in position sensing, and has there been any revenue from design wins?
A:NVE's sensors are uniquely positioned to use rare earth-free ferrite magnets. There has been some sales and interest in both the magnets and sensors, with concerns about rare earth magnets increasing.
Q:Can you comment on the current quarter, especially regarding the defense business?
A:The defense business has been relatively weak in past quarters, but there is optimism for a return to a more normal flow going forward.
Q:Does the rise in NRE revenues indicate additional future non-defense business?
A:Yes, NVE invests heavily in R&D, particularly in the medical space, and expects these investments to pay off in future sales.
Q:Are there any market gains in the two-year agreement with Abbott?
A:NVE cannot disclose specific devices Abbott uses its sensors in due to confidentiality. However, NVE is proud of its partnership with Abbott and other medical customers, promoting its products at trade shows.
Q:What is the potential for recurring customer orders to stabilize revenues?
A:NVE aims to grow sales with existing customers and add new products for them. Long-term customers like Abbott exemplify this strategy, contributing to revenue growth.
Q:Are the new medical customers similar to Abbott's applications, and why would medical robots need tiny parts?
A:NVE serves a variety of medical products, including life support devices, non-life support devices, and medical instruments. For medical robots, NVE's sensors offer high spatial sensitivity, enabling precise operations.
Q:Is MRAM an IP opportunity or a market opportunity with added capacity?
A:NVE specializes in high value-added memories for specialized applications like anti-tamper devices. The intellectual property is applicable to larger MRAMs, and NVE participates in the market through IP licensing.
Q:How will the new capacity impact the end market mix?
A:The new capacity targets emerging markets like the Internet of Things and artificial intelligence of things, focusing on industrial automation and smart factories.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the devices Abbott uses NVE's sensors in, citing confidentiality. Additionally, while there was optimism about the defense business returning to normal, the response lacked specific data or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounts month
Advanced Technology
Factories
President Advanced
SGA
Vice President
activity reassignment
asset purchase
bond
capability
cash
decrease RD
deduction
equipment service
income tax
increase product
increase tax
law change
margin decrease
payment
percentage
process
product RD
research development
resource manufacturing
sale decrease
sale distributor
size
state tax
tax law
tax rate
timing
NVEC Transcript
NVE Corporation (NVEC) Q3 2026 Earnings Call Transcript
Positive1-21
The earnings call reveals several positive aspects: ongoing production expansion, new product launches, and optimistic sales outlook in medical devices. The Q&A section highlights increased distributor sales, effective marketing efforts, and promising partnerships like Abbott. While there are some uncertainties, such as the nascent MagNav technology and lack of specific details in defense sector recovery, the overall sentiment is positive due to growth in key markets and strategic investments. The absence of negative financial surprises or guidance cuts further supports a positive stock movement prediction.
NVE Corporation (NVEC) Q2 2026 Earnings Call Transcript
Positive10-22
The earnings call shows promising signs of future growth with strong R&D results and expansion plans, especially in core markets. The company's focus on innovative products like wafer-level chip scale sensors and advanced magnetic switch sensors is expected to drive sales. While some responses were vague, the overall sentiment from the Q&A indicates optimism, particularly with upcoming growth drivers and industry recovery. The anticipation of significant cash flow savings and a strong pipeline further supports a positive outlook for stock price movement.
NVE Corporation (NVEC) Q1 2026 Earnings Conference Call Transcript
Positive7-23
The earnings call highlights strong financial performance with comprehensive income and positive operating cash flow, despite lower margins. The Q&A reveals growth expectations in the PUF business and potential in replacing rare earth metals. Strategic investments in wafer-scale packaging and patents on SOT RAM are promising. Although management was vague on certain reporting aspects, the overall sentiment is positive with anticipated growth in military orders and new market expansions, supporting a positive stock price movement.
NVE Corporation (NVEC) Q4 2025 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial metrics with high margins, a positive revenue outlook, and optimism in future demand, especially in medical and AI sectors. New product introductions and high isolation voltage devices are well-received. Despite increased expenses and a decrease in fiscal year revenue, the company's strategic R&D investments and strong profitability metrics suggest positive sentiment. The Q&A section indicates confidence in new business and product expansion. The quarterly dividend and lack of negative guidance further support a positive outlook, projecting a stock price increase of 2% to 8%.
NVEC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
